Company Filing History:
Years Active: 2014-2023
Title: Steven Charles DeFina: Innovator in Cancer Treatment
Introduction
Steven Charles DeFina is a notable inventor based in Oakland, CA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of pharmaceutical compounds. With a total of 2 patents, DeFina's work focuses on the development of MEK inhibitors and benzoxazepines, which are crucial in combating various proliferative diseases, particularly cancer.
Latest Patents
DeFina's latest patents include groundbreaking inventions that target cancer treatment. The first patent involves MEK inhibitors and methods of their use. This patent discloses compounds of Formula (I) and their pharmaceutically acceptable salts and solvates. These compounds are identified as MEK inhibitors, which are useful in treating proliferative diseases such as cancer. The patent also outlines pharmaceutical compositions containing these compounds and methods for their application in cancer treatment.
The second patent focuses on benzoxazepines as inhibitors of PI3K/mTOR and methods of their use and manufacture. This invention provides compounds that inhibit, regulate, and modulate PI3K and/or mTOR, which are essential in treating hyperproliferative diseases in mammals. The patent details methods for making these compounds and their use in treating various cancers, including breast cancer, renal cell carcinoma, and melanoma, among others.
Career Highlights
Steven Charles DeFina is currently associated with Exelixis, Inc., a company renowned for its focus on developing innovative cancer therapies. His work at Exelixis has positioned him as a key player in the pharmaceutical industry, contributing to advancements in cancer treatment.
Collaborations
DeFina collaborates with esteemed colleagues such as Naing N Aay and Joerg Bussenius. These collaborations enhance the research and development efforts at Exelixis, fostering an environment of innovation and discovery.
Conclusion
Steven Charles DeFina's contributions to cancer treatment through his patents and work at Exelixis, Inc. highlight his commitment to advancing medical science. His innovative approaches in developing MEK inhibitors and benzoxazepines are paving the way for new therapeutic options in the fight against cancer.